Category Archives

10 Articles

halotestin buy

It stimulates the halotestin buy central nervous system, has a tonic, hypertensive and hypoglycemic effect,hypotension, asthenic syndrome, physical and mental fatigue. Individual hypersensitivity to the drug, hypertension (high blood pressure), anxiety, epilepsy, convulsions, sleep disorders, acute infectious diseases, chronic liver disease. The drug is not recommended for use during pregnancy, lactation and children under 12 years.

 

Special instructions:

the drug should not be used in the halotestin buy second half of the day to avoid sleep disturbance.

 

Dosage and administration : inside for 30-40 minutes before eating 15-20 drops 2-3 times a day. The course of treatment 30-40 days. Whether to re-determined by the physician.

Side effects : allergic halotestin buy reactions, tachycardia, headache. In applying the drug may experience sleep disturbances, and hypoglycemia.

 

Interaction with other drugs:

possible potentiation of actions and analeptics stimulants (caffeine, camphor, amphetamine etc.) is a physiological antagonist drug agents which depress the central nervous system (including barbiturates, tranquilizers, sedatives, neuroleptics, etc.).

 

Product form : tincture in orange glass bottles of 50 ml.

Storage : in the dark place at a halotestin buy temperature of from 5 to 25 0 C, the reach of children.

Shelf life : 3 years. Do not use the drug after the expiry date stated on the package.

 

Conditions of supply of pharmacies:

without a prescription.

  steroiden kaufen

steroide kaufen deutschland

anabolika steroide kaufen

buy dianabol online winstrol 50 controlled delivery steroids steroidi anabolizzanti per dimagrire gh ormone cicli di steroidi anabolizzanti

halotestin for sale

A mixture halotestin for sale of non-uniform particles of vegetable raw dark green with orange, gray-brown and yellowish-white patches. The smell fragrant. Water extraction taste bitter, spicy, slightly a cooling. The mixture is non-uniform particles of vegetable raw materials brownish-green color with white, whitish-yellow, whitish-pink, yellow-orange, yellowish-brown and brown patches. The smell fragrant. Water extraction taste bitter, spicy, slightly a cooling.

The pharmacological action of
decoction or infusion of the collection has anti-inflammatory, antispasmodic, choleretic and mild laxative effect.

Indications for use
spasms of the gastrointestinal tract, constipation (as a mild laxative).

Contraindications
Hypersensitivity to halotestin for sale the drug; intestinal obstruction, spastic constipation, bleeding, acute abdomen syndrome, appendicitis and other inflammatory processes in the abdominal cavity, pregnancy, breastfeeding.

Dosing and Administration
About 5 grams (1 tablespoon) collection is placed in an enamel bowl, pour 200 ml (1 cup) of hot boiled water, close lid and heated in a boiling water bath for 30 minutes, cool 10 minutes at room temperature, filtered. The remaining raw materials squeeze. The volume of the resulting broth was adjusted with boiled water to 200 ml.

Is the inside of 1/2 cup in the morning and evening.
Decoction is recommended Shake before use.

Filter 2-Pack (4 g) was placed in a glass or enamel bowl, pour 200 ml (1 cup) of boiling water, cover and insist 30 minutes, occasionally pushing the spoon bags, then squeeze them. The volume of the resulting infusion was adjusted with boiled water to 200 ml.

Is the inside of 1/2 cup in the morning and evening.
Infusion halotestin for sale is recommended Shake before use.

Side effects:
Allergic reactions are possible. Prolonged use may thirst, headache, pain in the heart, weight loss, reduction or absence of laxative effect, constipation.
When possible overdose colicky abdominal pain.

Product Form
The ground raw material to 30 g, 35 g, 40 g, 50 g, 60 g, 75 g, 100 g of cardboard packs with an internal packet.
The powder in the filter bags of 2.0 g; 10 or 20 filter bags in cardboard packs.

Storage:
Store in a dry, dark place; decoction or infusion – in a cool place no more than 2 days.
Keep out of the reach of children.

Shelf life
2 years. Do not use beyond the halotestin for sale expiration date printed on the package.

Conditions of supply of pharmacies
without a prescription. azolol review steroids anabolic for sale jeff seid steroids anabolic steroids facts

fluoxymesterone halotestin

Fluoxymesterone halotestin is hypertonic colloidal solution has antishock effect. The therapeutic effect is associated with fluoxymesterone halotestin created them in the lumen of blood vessels high colloid osmotic pressure (220-290 mm water column). Increased circulating plasma (more than 1.5 times the magnitude of the outgoing) and a blood pressure increase is not only due to the injected solution, but also due to additional intake into the vascular interstitial fluid. fluoxymesterone halotestin increased erythrocyte sedimentation rate, which is normalized by an average of 20 days; It does not violate the protein, carbohydrate and pigment of the liver; improves microcirculation.
fluoxymesterone halotestin krovyanosnoe quickly leaves the track, due to the large number of low molecular weight fractions (2 hours in the blood is about 20% of the administered drug). The bulk of the drug is excreted from the body by the kidneys (in the first day 40% of the drug in vtorye- 1%). The remaining portion penetrates from the vascular tissue, where the tissue is exposed to enzymes – and proteases involved in protein metabolism.

The drug is administered intravenously or intraarterially, regardless of the group crore.
In acute blood loss and shock recommended intravenous jet with subsequent transition to drip (50-60 drops to 1 minute) to maintain blood pressure at the physiological level. The dose depends on the patient’s condition. When necessary, designate fluoxymesterone halotestin again. At the same time not more than 2 liters of solution may be introduced. Children -. To a maximum of 15-25 mg / kg body weight
for extracorporeal circulation fluoxymesterone halotestin applies together with donor red blood cells in different proportions and with the addition of other solutions.

Side effects
Albuminuria (within 1-2 days after the administration). In very rare cases may cause allergic reactions of varying severity
should keep in mind the danger of anaphylactic shock in patients at risk, having in the anamnesis intolerance of drugs, including serums, vaccines and intravenous protein preparations, plazmozameshchath preparations, including preparations of dextran.
in the event of adverse reactions, the infusion should be discontinued immediately and without removing the needle from the vein, enter antihistamines, decongestants and corticosteroids, pressor agents used in the treatment of anaphylactic shock.

Cautions
Before transfusion fluoxymesterone halotestin doctor should perform a visual inspection designed for infusion bottles. The drug is considered to be suitable for use while maintaining sealing leaks, cracks in the bottles. The drug should be transparent and free from suspended matter.
The results of the visual inspection of bottles and labels data (name of the drug, the manufacturer, serial number) must be recorded in the history of the patient’s disease. When applying fluoxymesterone halotestin necessarily holding a biological sample: after the first administration of 5 drops of infusion was stopped for 3 minutes and then another 30 drops administered again and stop infusion for 3 minutes in the absence of undesirable reaction continued drug administration. The test results must be recorded in the history of the disease.

Interaction with other medicinal products
is compatible with nitrogen-containing preparations for parenteral nutrition, vitamins, glucose solution in different proportions, blood and its components.

Product form
Solution for infusion in 450 ml glass bottles, sealed with rubber stoppers and run-aluminum caps. 15 bottles of 10 instructions for use in boxes made of cardboard.

Storage conditions
In a dry place at a temperature of 4-22 ° C.
Keep out of reach of children.

Shelf life
4 years. The drug should be used before the date printed on the package. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo. testosterone reviews bodybuilding pain o soma healthy food for bodybuilding

buy halotestin

 

The contraceptive buy halotestin effect Jeanine performed by complementary mechanisms, the most important of which are inhibition of ovulation and changes in cervical mucus viscosity, causing it becomes impenetrable to sperm.When used properly, Pearl index (an indicator of the number of pregnancies in 100 women taking contraceptive during the year) is less than 1. When skipping pills or incorrect use Pearl Index may increase.Jeanine progestogens component – dienogest – has anti-androgenic activity, as confirmed by the results of several clinical studies. Furthermore, dienogest improves blood lipid profile (increases the amount of high density lipoprotein).In women receiving combined oral contraceptives, menstrual cycle becomes more regular, more rarely observed painful menstruation, decreases the intensity and duration of bleeding, thus reducing the risk of iron deficiency anemia. Furthermore, there is evidence of reducing the risk of endometrial cancer and ovarian cancer.

Pharmacokinetics

· Dienogest

Absorption. When taken orally dienogest is rapidly and completely absorbed, its maximum serum concentration equal to 51 ng / ml, is reached in about 2.5 hours. The bioavailability is approximately 96%.

Distribution. Dienogest bound to albumin serum, and is not associated with binding globulin sex steroids (SHBG) and corticoid-binding globulin (CBG). The free form is about 10% of the total serum concentration; about 90% – non-specifically bound to serum albumin. Induction of synthesis of SHBG ethinylestradiol not affect the binding to serum protein dienogest.

Metabolism. Dienogest almost completely metabolized. Clearance of serum after a single dose of about 3.6 l / h.

. Elimination half-life is about 8,5-10,8 h A small number in unchanged form excreted by the kidneys as metabolites (half-life – 14.4 hours.) Which are excreted by the kidneys and the gastrointestinal tract in a ratio of about 3.: 1.

The equilibrium concentration . Pharmacokinetics dienogest not affect SHBG levels in serum. As a result, the drug substance daily serum increased about 1.5 times.

· Ethinylestradiol

Absorption . After oral administration, ethinylestradiol is rapidly and completely absorbed. Maximum serum concentration equal to approximately 67 pg / ml, achieved after 1.5-4 hours. During the suction and the first passage through the liver is metabolized ethinylestradiol, whereby its oral bioavailability averages about 44%.

Distribution . Ethinyl estradiol is almost full (about 98%), while non-specifically binds to albumin. Ethinyl estradiol induces the synthesis of SHBG. The apparent volume of distribution of ethinylestradiol is 2.8 – 8.6 l / kg.

Metabolism . Ethinylestradiol undergoes conjugation presistemna as mucosa of the small intestine and in the liver. The main pathway – aromatic hydroxylation. The rate of plasma clearance of 2.3 – 7 ml / min / kg. Excretion. The decrease in serum concentration of ethinyl estradiol is biphasic; The first phase is characterized by a half-life of about 1 hour, the second – 10-20 hours. In an unmodified form of the organism is not displayed. Ethinylestradiol metabolites are excreted in the urine and bile in a ratio of 4: 6. With a half-life of about 24 hours . The equilibrium concentration of the equilibrium concentration is achieved during the second half of the treatment cycle.

 

Indications

Contraception.

Contraindications

Janine should not be applied if any of the conditions / diseases listed below. If any of these conditions develop for the first time on his patients receiving the drug should be immediately repealed.

 

· Thrombosis (venous and arterial) and thromboembolism present or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders.

· Conditions prior thrombosis (including transient ischemic attack, angina pectoris) now or in history.

· Migraine with focal neurological symptoms in the present or in history.

· Diabetes mellitus with vascular complications.

· Multiple or severe venous or arterial thrombosis risk factors, including complicated lesions valvular atrial fibrillation, cerebrovascular disease, or coronary arteries; uncontrolled hypertension, major surgery with prolonged immobilization, smoking at the age of 35 years.

· Pancreatitis with severe hypertriglyceridemia now or in history.

· Liver failure and severe liver disease (liver function tests before normalization).

· Liver tumors (benign or malignant) now or in history.

· Identified hormone malignancies (including genital or mammary glands) or are suspected.

· Vaginal bleeding of unknown origin.

· Pregnancy or suspicion of it.

· The period of lactation.

· Hypersensitivity to any component of the drug Janine.

 

 

C caution

You should carefully weigh the potential risks and expected benefits of the use of combined oral contraceptives in each individual case in the presence of the following diseases / conditions and risk factors:

 

· Risk factors for thrombosis and thromboembolism: smoking; obesity; dislipoproteinemia, hypertension; migraine; valvular disease; prolonged immobilization, major surgery, major trauma; a genetic predisposition to thrombosis (thrombosis, myocardial infarction or cerebrovascular accident at a young age in any of the next of kin)

· Other diseases in which may occur peripheral circulatory disorders: diabetes; systemic lupus erythematosus; hemolytic uremic syndrome; Crohn’s disease and ulcerative colitis; sickle cell anemia; phlebitis of superficial veins

· Hereditary Angioedema

· Hypertriglyceridemia

· Liver disease

· Diseases caused or aggravated first time during pregnancy, or on the background of the previous use of sex hormones (eg, jaundice, cholestasis, gallbladder disease, otosclerosis with hearing impairment, porphyria, herpes gestationis, Sydenham’s chorea)

· Postpartum

 

Pregnancy and lactation

Janine is not appointed during pregnancy and lactation.

If pregnancy is detected during the reception of Janine drug, the drug should be immediately abolished. However, extensive epidemiological studies have revealed no increased risk of defects in children born to women treated with hormones before pregnancy, or teratogenic effects when sex hormones were taken inadvertently in early pregnancy.

Admission combined oral contraceptives can reduce the amount of breast milk and change its composition, so their use is contraindicated during lactation. A small amount of sex steroids and / or their metabolites may be derived from milk.

Dosing and Administration

Drops should be taken orally in the order indicated on the package, every day at about the same time, with a little water. Take one tablet a day continuously for 21 days. Receiving the next pack is started after a 7-day break in taking pills, during which withdrawal bleeding usually occurs. Bleeding usually begins 2-3 days after the last pellet and can not end before receiving the pills from a new package.

How to start taking Jeanine

· If you do not receive any hormonal contraceptive use in the preceding month.

Janine Reception begins on the first day of the menstrual cycle (ie the first day of menstrual bleeding). Shall start receiving 2-5 days of the menstrual cycle, but in this case it is recommended to additionally use a barrier method of contraception during the first 7 days of tablet-taking from the first package.

· When switching from other combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, transdermal patch).
Preferably start accepting Janine the next day after taking the last active pills from the previous package, but in any case not later than the day after the usual 7-day interval (for formulations containing 21 tablet) or after the last inactive tablets (for formulations containing 28 tablets per pack). In the transition from a vaginal ring, transdermal patch preferably start taking Jeanine day remove the ring or patch, but not later than the day when it should be inserted a new ring or pasted a new patch.

· When switching from contraceptives containing only progestin ( “mini-pill”, an injectable form, implant) or releasing progestogen IUD (Mirena).
A woman can go to the mini-pill to Jeanine any day (without a break), with the implant or intrauterine device with progestin – the date of its removal from the injection mold – the day when the next injection should have to be made. In all cases, you must use an additional barrier method of contraception during the first 7 days of tablet-taking.

· After an abortion in the first trimester of pregnancy.
A woman may start taking the drug immediately. Subject to this condition the woman does not need additional contraceptive protection.

· After delivery or abortion in the second trimester of pregnancy.
It is recommended to start taking the drug on day 21-28 after delivery or abortion in the second trimester of pregnancy. If the reception is started later, you must use an additional barrier method of contraception during the first 7 days of tablet-taking. However, if a woman has been sexually active, before you start taking Jeanine pregnancy should be excluded or must wait for the first menstrual period.

Admission missed pills

If the delay in receiving the drug was less than 12 hours , contraceptive protection is not reduced. The woman should take pills as soon as possible, should be taken at the usual time.

If the delay in taking pills made more than 12 hours , contraceptive protection may be reduced. It is possible to be guided by the following two basic rules:

· The drug should never be interrupted for more than 7 days.

· 7 days continuous administration of pills required to achieve adequate suppression of the hypothalamic-pituitary-ovarian regulation.

Accordingly, these tips may be given if the delay in receiving a dragee was 12 hours (the interval since last receiving pellets over 36 hours):

· The first week of taking the drug

The woman should take the last missed pills as soon as possible, as soon as you remember (even if this means taking two pills at once). Next take the pills at the usual time. Additionally, it should be used a barrier method of contraception (such as a condom) for the next 7 days. If intercourse took place during the week before skipping pills, you need to take into account the chance of pregnancy. The more pills missed and the closer they are to a break in the reception of active substances, the greater the likelihood of pregnancy.

· The second week of taking the drug

The woman should take the last missed pills as soon as possible, as soon as you remember (even if it needs to take two pills at the same time). Next take the pills at the usual time.

Provided that the woman has taken pills correctly in the 7 days preceding the first missed pills, there is no need to use additional contraceptive measures. Otherwise, as well as skipping of two or more must be added dragees barrier methods (such as condoms) for 7 days.

· The third week of taking the drug

The risk of reduced reliability is imminent because of the forthcoming break in taking pills.

A woman should strictly adhere to one of the two following options. Moreover, if during the 7 days preceding the first missed pills, all the pills are taken correctly, there is no need to use additional contraceptive methods.

1. The woman should take the last missed pills as soon as possible, as soon as you remember (even if this means taking two pills at once). Next take the pills at the usual time until the end of the current package of pills. The next pack should be started immediately. Withdrawal bleeding is unlikely until the end of the second pack, but may experience spotting and breakthrough bleeding during the tablet-taking.

2. The woman may also interrupt the reception of pills from the current package. Then she should take a break for 7 days, including the day of skipping pills, and then start taking a new package.

If a woman misses pills, and then during a break in taking pills she had no withdrawal bleeding, pregnancy must be excluded.

Recommendations in case of vomiting and diarrhea

If a woman has had vomiting or diarrhea within 4 hours after taking the active pills, absorption may not be complete and should be additional contraceptive measures are taken. In these cases, you should be guided by the recommendations by skipping pills.

Changing the date of the beginning of the menstrual cycle

In order to delay the onset of menstruation, the woman should continue taking pills from a new package Jeanine immediately after taking all the pills from the previous one, without a break in the reception. Drops of this new packaging may be taken for as long as the woman wants (as long as the packaging is not finished). Against the background of the drug from the second package, women may experience spotting or breakthrough uterine bleeding. Resume Jeanine reception from a new package follows the usual 7-day break.

In order to move the first day of menstruation to another day of the week, the woman should be reduced the next break in taking pills for as many days, as much as she wants. The shorter the interval, the higher the risk that she will not have withdrawal bleeding, and in the future, will be spotting and breakthrough bleeding while taking second pack (just as when she wanted to delay the onset of menses).

Additional information for special categories of patients

Children and adolescents

The drug Jeanine shown only after menarche.

Elderly patients

Not applicable. The drug Jeanine not shown after menopause.

Patients with disorders of the liver

Jeanine drug is contraindicated in women with severe liver disease as long as liver function tests have not come back to normal. See. Also “Contraindications”.

Patients with disorders of the kidney

The drug Jeanine not specifically studied in patients with disorders of the kidneys. Available data do not suggest changes in the treatment of such patients online anabolic steroids pharmacy

bradley martyn steroids

anabolic steroids buy online

halotestin

It halotestin inhibits gonadotropic pituitary function, inhibits follicular development and prevent ovulation process. The contraceptive effect is also enhanced by increasing the viscosity of halotestin cervical secretions and reduce the susceptibility of the endometrium to the blastocyst. Pearl (0.90) The index reflects the frequency of pregnancy in 100 women over 12 months of application of the chosen method of contraception.
Pregnancy rate does not depend on age, race, but increases in women weighing over 90 kg.

Halotestin concentrations norelgestromina and ethinyl estradiol in the blood plasma reaches steady-state values 48 hours after application of the transdermal patch Evra ® and up 0.8 ng / ml and 50 pg / ml, respectively. With long-term use of the transdermal patch Evra ® equilibrium concentration (C ss ) and area under the curve “concentration-time» (AUC) increase somewhat. At different temperatures and physical exertion are no significant changes in C ss and AUC norelgestromina and AUC of ethinyl estradiol increased somewhat during exercise, whereas the C ss remains unchanged. Targets are the C ss norelgestromina and ethinyl estradiol are maintained for 10 days of application of the patch transdermal Evra ® , those. Clinical efficacy of transdermal patch can be maintained even if a woman will hold its regular replacement of 2 full days after the scheduled seven-day period. The distribution Norelgestromin and norgestrel (serum metabolite norelgestromina) have a high (> 97%) of plasma protein binding. Norelgestromin binds to albumin, norgestrel binds preferentially to globulins, sex hormone binding. Ethinylestradiol has a high degree of binding to plasma albumin. Biotransformation Norelgestromin metabolized in the liver to form metabolite norgestrel, and various hydroxylated and conjugated metabolites. Ethinyl estradiol is metabolized to various hydroxylated compounds and their glucuronide and sulfate conjugates. Progestogens and estrogens inhibit many enzymes of the cytochrome P-450 (including CYP 3A4, CYP 2C19) in human liver microsomes. Elimination average half-life norelgestromina and ethinyl estradiol is about 28, and 17 hr, respectively. Metabolites norelgestromina and ethinyl estradiol are eliminated by the kidneys and the bowel. The influence of age, body weight and body surface area values of the C ss and AUC of ethinyl estradiol and norelgestromina slightly decreased with increasing age, body weight or body surface area.

 

Indications

Contraception for women.

Contraindications

Evra transdermal patch ® is contraindicated in women with the following conditions:

  • thrombosis (arterial and venous) and thromboembolism currently or history (including thrombosis, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cerebrovascular disease);
  • state prior thrombosis (including transient ischemic attack, angina) currently or history;
  • hereditary predisposition for venous or arterial thrombosis, including Activated protein C resistance, antithrombin III deficiency, protein C deficiency, protein deficit S, hyperhomocysteinemia, antiphospholipid antibodies (antibodies to cardiolipin, lupus anticoagulant), etc .;
  • multiple or severe venous or arterial thrombosis risk factors, including complicated lesions valvular, subacute bacterial endocarditis, atrial fibrillation, cerebrovascular disease, or coronary artery disease, uncontrolled hypertension, smoking at the age of 35 years, hereditary dislipoproteinemia, three-dimensional surgical interference with prolonged immobilisation, obesity (body mass index over 30 kg / m 2 , calculated as the ratio of weight in kilograms to the square of the height in meters);
  • diabetes with vascular disease;
  • migraine with focal neurological symptoms;
  • confirmed or suspected breast cancer;
  • diagnosed (including history) estrogen-dependent cancers (such as cancer of the endometrium) or are suspected;
  • vaginal bleeding of unknown etiology;
  • cholestatic jaundice during pregnancy or jaundice while using hormonal contraceptives before;
  • acute or chronic liver disease with impaired liver function;
  • benign or malignant liver tumors;
  • postpartum period (4 weeks);
  • known or suspected pregnancy;
  • lactation;
  • Hypersensitivity to the drug;
  • age 18 years.

Be wary
– venous or arterial thromboembolism in siblings or parents at a relatively young age,
– thrombophlebitis of superficial veins and varicose veins;
– controlled hypertension;
– severe migraine without focal neurological symptoms;
– diabetes without vascular complications;
– existing (or history), severe depression;
– existing (or history) gallstone disease;
– chronic idiopathic jaundice;
– cholestatic jaundice, a family history (eg syndromes rotor, Dubin-Johnson);
– acute impairment of liver function during the previous pregnancy or previous the use of sex hormones,
– systemic lupus erythematosus;
– ulcerative colitis
– Crohn’s disease;
– gipertriglitserilemiya;
– hemolytic uremic syndrome
– Sydenham’s chorea;
– porphyria;
– herpes during pregnancy;
– otosclerosis;
– multiple sclerosis;
– chloasma;
– uterine fibroids and endometriosis;
– the presence of relatives of the first line of kinship with breast cancer.

Use during pregnancy and lactation.

Evra transdermal patch ® is contraindicated during pregnancy and lactation.

Dosing and Administration

The dose
cutaneous
To achieve maximum contraceptive effect women have used the patch transdermal Evra ® in strict accordance with the instructions. The instructions concerning the beginning of the patch transdermal Evra ® , shown below in the section “How to start the use of the patch transdermal Evra ® “. At the same time, you can only use one patch transdermal Evra ® . Each used patch transdermal Evra ® is removed and immediately replaced with a new one the same day of the week ( “day replacement”) on the 8th and the 15th days of the cycle of the drug (2nd and 3rd week ). Evra transdermal patch® can be changed at any time to replace the day. During the 4th week, from 22 th to 28 th day of the cycle, a transdermal patch Evra ® is not used. A new contraceptive cycle begins on the next day after the end of the 4th week; next transdermal patch Evra ® should be pasted, even if the bleeding menstrualnopodobnoe “cancellation” has not been or is not over. Under no circumstances should a break in wearing the transdermal patch Evra ® should not be more than 7 days, otherwise it increases the risk of pregnancy. In such situations, for 7 days at the same time you need to use a barrier method of contraception, since the risk of ovulation increases with each day of exceeding the recommended length of time, free from the use of a transdermal patch Evra ® . In the case of sexual intercourse during this period increased the probability of conception is very high.

 

Dosing
patch transdermal Evra ® should stick to a clean, dry, intact and healthy skin of the buttocks, abdomen, outer surface of the upper arm or upper body with minimal body hair, in areas where it will not come into contact with a tight-fitting clothing.
In order to avoid possible irritation every next transdermal patch Evra ® is necessary to stick to a different area of the skin, it can be done within the same anatomical region. Unacceptable use transdermal patch on the breast.
The patch transdermal Evra ® should be tightly pressed to the edges of good contact with the skin. To avoid reducing the adhesive properties of the patch transdermal Evra ® should not be applied make-up, creams, lotions, powders and other local resources to those areas of the skin where it is glued or be bonded.
A woman should daily inspect patch transdermal Evra ® in order to be confident in his firmly secured.
The used transdermal patch must be carefully disposed of in accordance with the recommendations.

Disposal
Since the used transdermal patch contains significant amounts of active ingredients, it must be disposed of carefully. For this special adhesive film is separated from the outside of the bag. Place the used transdermal patch in the sachet so that its adhesive side facing the painted area on the bag, and lightly pressed for sealing. Sealed packet is discarded. The used transdermal patch should not be thrown in the toilet or down the drain.

How to start the use of the transdermal patch Evra ® If during the previous menstrual cycle has not applied the hormonal contraceptive Contraception using the transdermal patch Evra ® begin on the first day of menstruation. Glued to the skin of a transdermal patch Evra ® and use it throughout the week (7 days). Day of bonding the first transdermal patch Evra ® (1 day / day of the beginning) specifies the following days replacement. Replacing Day will fall on the same day each week (8 th and 15 th days of the cycle). On the 22 th day of transdermal patch cycle is removed, and from 22 th to 28 th day of the cycle woman is not using the transdermal patch Evra ® . The next day is the first day of a new contraceptive cycle. If a woman begins to use a transdermal patch Evra ® is not the first day of menstruation, it is necessary to simultaneously use a barrier method of contraception during the first 7 days of the first contraceptive cycle.

 

If a woman goes to a combined oral contraceptive drug on the use of transdermal patch Evra ®
patch transdermal Evra ® should stick to the skin on the first day of bleeding menstrualnopodobnoe “cancel”, which began after the discontinuation of the combined oral contraceptive. Menstrualnopodobnoe If bleeding does not start within 5 days after receiving the contraceptive pill, it is necessary to exclude pregnancy before starting the use of the transdermal patch Evra ® . If the application of Evra ® starts after the first day of bleeding menstrualnopodobnoe, within 7 days you must simultaneously use barrier methods of contraception. If, after taking the last contraceptive pill has been more than 7 days, then the woman may have ovulated and therefore she should consult a doctor before starting to apply the patch Evra transdermal ® . Sexual intercourse during this prolonged period, receiving free contraceptive tablets may lead to pregnancy.

If a woman goes to the contraceptive pills containing progestogen only, the use of the patch transdermal Evra ®
She can any day to move from the use of a preparation containing only a progestogen (the day of implant removal, on the day when the next injection should be done), but for the first 7 days of treatment with transdermal patch Evra ® should use a barrier method for enhancing effectiveness.

After an abortion or miscarriage
After an abortion or miscarriage before the 20th week of pregnancy, you can immediately begin applying transdermal patch Evra ® . If a woman begins to apply the patch Evra transdermal ® immediately after an abortion or miscarriage, to resort to an additional method of contraception is not required. A woman should know that ovulation may occur within 10 days after an abortion or miscarriage.
After an abortion or miscarriage in the 20th week of pregnancy or later, use the patch transdermal Evra ® can begin on the 21st day after an abortion or miscarriage or on the first day the first ensuing menstruation (whichever comes first).

After childbirth
women are not breastfeeding her baby can start applying the patch Evra transdermal ® no earlier than 4 weeks after giving birth. If a woman begins to apply the patch Evra transdermal ® later, during the first 7 days it must additionally use a barrier method of contraception. If there was a sexual contact, it is necessary to exclude pregnancy before starting the use of the transdermal patch Evra ® , or the woman has to wait for the first menstrual period.

At full or partial peeling off transdermal patch Evra ®
If transdermal patch Evra ® is fully or partially come off, then the blood flows insufficient number of its active ingredients.
Even with partial peeling off transdermal patch Evra ®

  • less than during the day (up to 24 hours) should be re-glue patch transdermal Evra ® in the same place or immediately replace it with a new transdermal patch Evra ® . Additional contraception is not required. Next transdermal patch Evra ® is necessary to stick to a regular “day of replacement.”
  • more than during the day (24 hours or more), and if the woman does not know exactly when the patch Evra transdermal ® partially or completely come off: possible pregnancy. The woman should immediately start a new cycle, a new patch transdermal gluing Evra ® and consider this day the first day of contraceptive cycle. Barrier methods of contraception should be used at the same time only during the first 7 days of the new cycle.

Do not attempt to re-glue patch transdermal Evra ® , if it has lost its adhesive properties; instead, you must immediately stick the new patch transdermal Evra ® . You can not apply additional adhesive tape or bandage to keep the transdermal patch in place Evra ® .

If you skipped the next day replacement transdermal patch Evra ®

At the beginning of any contraceptive cycle (Week 1 / Day 1):
If the increased risk of pregnancy a woman should first stick the patch Evra transdermal ® a new cycle immediately as soon as you remember about it. This day is considered the new “1st day” and counted the new “day of replacement.” Barrier methods of contraception should be used concurrently for the first 7 days of the new cycle. In the case of sexual intercourse during the extended period of time without the use of contraception can occur conception. In the middle of the cycle (Week 2 / Day 8 or Week 3/15-Day):

  • from the date of replacement have been one or two days (48 hours): the woman should immediately stick the new patch transdermal Evra ® . Next transdermal patch Evra ® is necessary to stick to a regular “day of replacement.” If during the 7 days preceding the first skipped day of transdermal patch attachment Evra ® , a woman properly applied transdermal patch Evra ® , no additional contraceptive protection is needed;
  • It has passed since the replacement of more than two days (48 hours or more): there is an increased risk of pregnancy. Women should stop the current contraceptive cycle and immediately start a new 4-week cycle, pasted a new patch transdermal Evra ® . This day is considered the new “1st day” and counted the new “day of replacement.” Barrier contraception must be used simultaneously for the first 7 days of the new cycle;
  • at the end of the cycle (Week 4 / Day 22): If the transdermal patch Evra ® is not removed at the beginning of the 4th week (22-day), then it should be removed as soon as possible. Another contraceptive cycle must begin at the normal “day replacement,” which is the next day after the 28th day. Additional contraception is not required.

Changing the date of replacement
if a woman finds it necessary to replace the transfer date, the current cycle should be completed. Removing third transdermal patch Evra ® should be made in an ordinary day replacement. During the week, free applications, a woman may choose a new day replacement, gluing the first transdermal patch Evra ® the next cycle on the chosen day. Period, free from the use of a transdermal patch Evra ® , in any case should not exceed 7 days. The shorter the period, the greater the likelihood that a woman will not be another menstrualnopodobnoe bleeding, and during the next cycle contraceptive may occur acyclic abundant or scanty bleeding. eminence labs